Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008Chezi Ganzel, Judith Manola, Dan Douer, et al.
Leukemia Research|January 16, 2021
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre studyTamir Shragai, Moshe E Gatt, Adir Shaulov, et al.
Leukemia & Lymphoma|September 14, 2017
Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?Ohad S Bentur, Ronit Gurion, Anat Gafter-Gvili, et al.
American Journal of Hematology|October 6, 2015
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemiaYishai Ofran, Ronit Leiba, Chezi Ganzel, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
American Journal of Hematology|June 16, 2018
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experienceChezi Ganzel, Zhuoxin Sun, Larry D Cripe, et al.
Leukemia & Lymphoma|May 19, 2020
Venetoclax is safe and efficacious in relapsed/refractory AMLChezi Ganzel, Ron Ram, Alexander Gural, et al.
British Journal of Haematology|May 23, 2024
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemiaEitan Kugler, Inbar Cohen, Irina Amitai, et al.
Blood Advances|December 5, 2024
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort studyOfir Wolach, Itai Levi, Boaz Nachmias, et al.
British Journal of Haematology|October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective studyTamir Shragai, Hila Magen, Noa Lavi, et al.
Pageof 5